Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day)
treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral
load from the late pregnancy until the delivery date or postpartum 1 month.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Collaborators:
Fifth People's Hospital of Anyang First Affiliated Hospital of Nanyang Medical College Henan Provincial People's Hospital Luohe Central Hospital Luoyang Central Hospital Nanyang Central Hospital National Natural Science Foundation of China Second Affiliated Hospital of Xi'an Jiaotong University Shandong Provincial Hospital Sixth People's Hospital of Kaifeng The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The Sixth People's Hospital of Zhengzhou Xinyang Central Hospital Yan'an University Affiliated Hospital